Milestone Scientific, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US59935P2092
USD
0.35
0 (1.37%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Milestone Scientific, Inc. stock-summary
stock-summary
Milestone Scientific, Inc.
Pharmaceuticals & Biotechnology
Milestone Scientific Inc. (Milestone) is engaged in providing computer-controlled injection technologies and solutions for the medical and dental markets. The Company uses its CompuFlo technology for the delivery of medicaments. The CompuFlo pressure or force Computer-Controlled Local Anesthetic Delivery (C-CLAD) technology is a medical technology for the delivery of drugs, anesthetics and other medicaments into various tissue types. Milestone's product portfolio includes Single Tooth Anesthesia Instrument (STA Instrument), CompuDent, CompuMed and The Wand. The Company's STA Instrument is a computer-controlled local anesthesia delivery instrument that utilizes the pressure feedback elements of Milestone's CompuFlo technology. CompuDent (also known as the Wand Plus internationally) is Milestone's C-CLAD instrument. CompuMed is a computer-controlled injection instrument offered by the Company. The Wand handpiece is used in conjunction with the STA, CompuDent and CompuMed instruments.
Company Coordinates stock-summary
Company Details
220 S Orange Ave , LIVINGSTON NJ : 07039-5804
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (4.0%)

Foreign Institutions

Held by 7 Foreign Institutions (0.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Leslie Bernhard
Independent Non-Executive Chairman of the Board
Mr. Leonard Osser
Director
Mr. Gian Trombetta
Director
Mr. Neal Goldman
Independent Director
Mr. Michael McGeehan
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 48 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.10

stock-summary
Return on Equity

-208.80%

stock-summary
Price to Book

14.26